CURRICULUM VITAE

Christopher George Parker, Ph.D.

Department of Chemistry, The Scripps Research Institute 561-228-2785 [email protected] parkerresearch.org

Education

2007–2013 Ph.D., Chemistry Yale University, New Haven, CT Research Advisor: David A. Spiegel

2007–2009 M.S., Chemistry Yale University, New Haven, CT

2003–2007 B.S., Chemistry (Cum Laude and Highest Departmental Honors) Minor Biology Case Reserve University, Cleveland, OH Research Advisor: Phil P. Garner

Professional Experience

2018–present Assistant Professor Department of Chemistry The Scripps Research Institute, (Jupiter) and (San Diego) campuses

2013–2018 American Cancer Society Postdoctoral Research Fellow Department of Molecular Medicine The Scripps Research Institute Research Advisor: Prof. Benjamin F. Cravatt III, Ph.D.

Awards and Honors

2020 Idea Development Award for the Lung Cancer Research Program, DoD 2017 Aspen Cancer Conference Fellow 2014-2017 American Cancer Society Postdoctoral Fellowship 2009 Dox Fellowship in Recognition of Excellence in Academics and Research in Organic Chemistry 2008 T.F. Cooke Award for Teaching Assistant Excellence 2007 Polymer Valley Chemical Undergraduate Research Award 2006 GlaxoSmithKline (GSK) Undergraduate Research Fellowship

1 Curriculum Vitae Christopher G. Parker, Ph.D 2005 Howard Hughes Medical Institute (HHMI) Undergraduate Research Fellowship 2005 Merck Index Award 2005-2007 Case Western Reserve Alumni Scholarship 2003-2007 Case Western Reserve Full Tuition Scholarship

Publications

*co-corresponding authors; #authors contributed equally to this work

1. Joeh, E.; O'Leary, T.; Li, W; Hawkins, R.; Hung, J.; Parker, C.G.; Huang, M.L. “Mapping glycan-mediated galectin-3 interactions by live cell proximity labeling” bioRxiv preprint, 2020, doi.org/10.1101/2020.05.09.058586

2. Pratt, M.R.*; Parker, C.G.* “Click Chemistry in Proteomic Investigations” Cell, 2020, 180, 605.

3. Gallo, L.; Wei, W.; Jadhav, A.; Parker, C.G. “The Druggability of Solute Carriers” J. Med Chem, 2020, 63, 3834.

4. Galmozzi, A; Kok, B.; Kim, A.; Montenegro-Burke, J.R.; Lee, J.; Spreafico, J.; Albert, V.; Cintron-Colon, R.; Godio, C.; Webb, W.; Conti, B.; Parker, C.G.; Peluso, J. J.; Pru, J.K.; Siuzdak, G.; Cravatt, B.F.; Saez, E. “PGRMC2 is an Intracellular Heme Chaperone Critical for Adipocyte Function” Nature, 2019, 575, 138.

5. Wang, Y.; Dix, M.M.; Remsberg, J.R.; Lee, H.Y.; Kalocsay, M.; Gygi, S.P.; Vite, G.; Lawrence, R.M.; Parker, C.G.*; Cravatt, B.F.* “Expedited Mapping of the Ligandable Proteome Using Fully Functionalized Enantiomeric Probe Pairs” Nature Chemistry, 2019, 11, 1113.

Preprint posted to ChemRxiv (27.02.2019), doi:10.26434/chemrxiv.7764638.v1

6. Parker, C.G.*; Cravatt, B.F.* “Chemistry Takes Center Stage for Identifying Cancer Targetability” Cell, 2018, 173, 815.

7. Galmozzi, A.#; Parker, C.G.#; Kok, B. P.; Cravatt, B.F.; Saez, E. “Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments” Methods Mol Biol, 2018, 1787, 115.

8. Parker, C. G.*; Kuttruf, C. A.; Galmozzi, A.; Jorgensen, L.; Chein-Hung, Y.; Hermanson, D.H.; Wang, Y.; Perez, M.E.; McKerrall, S.J.; Joslyn, C. J; Duenstl, G.; Felding, J.; Saez, E.; Baran, P.S.*; Cravatt, B.F*. “Chemoproteomic Profiling Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs” ACS Cent Sci, 2017, 3, 1276.

9. Schonhoft, J.D.#; Monteiro, C.#; Plate, L.; Eisele, Y.S.; Kelly, J.; Boland, D.; Parker, C.G.; Cravatt, B.F.; Berk, J.; Sekijima, Y.; Maurer, M.; Novais, M.; Coelho, T.; Powers, E.T.; Kelly,

2 Curriculum Vitae Christopher G. Parker, Ph.D J.W. “Peptide Probes Detect Misfolded Transthyretin Oligomers in the Plasma of Early Stage Hereditary Amyloidosis Patients” Science Translational Medicine, 2017, 9, eaam7621.

10. Parker, C. G.*#; Galmozzi, A.*; Wang, W.; Correia, B. E.; Sasaki, K.; Joslyn, C. J.; Kim, A. S.; Cavallaro, C. L.; Lawrence, M.; Johnson, S. R.; Saez, E.*; Cravatt, B. F.* “Ligand and target discovery by fragment-based screening in human cells” Cell, 2017, 168, 527-541.

11. Parker, C.G.; Dahlgren, M.K.; Li, D.T.; Jawanda, N.; Shoda, T.; Spasov, K.A.; Domaoal, R.A.; Sutton, R.; Anderson, K.S.; Jorgensen, W.L.; Spiegel, D.A. ”Illuminating gp120–Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules,” Chemical Science, 2014, 5, 2311-2317.

12. Jakobsche, C.E.*; Parker, C.G.* Tao, R.N.; Kolesnikova, M.D.; Spiegel, D.A. “Comparing Activities and Prevalence of Natural Antibody Populations from Human Serum,” ACS Chemical Biology, 2012, 7, 1139-1151.

13. McEnaney, P. J.*; Parker, C.G.*; Zhang, A.X.* Spiegel, D.A. “Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease,” ACS Chemical Biology, 2012, 7, 1139-1151.

14. Parker, C.G.; Domaoal, R.A.; Anderson, K.S.; Spiegel, D.A. “An Antibody-Recruiting Small Molecule That Targets HIV gp120,” J. Am. Chem. Soc., 2009, 131, 16392-16394.

15. Garner, P.; Hu, J.; Parker, C. G.; Youngs, W. J.; Medvetz, D. "The Cu(I) Catalyzed Exo- Selective Asymmetric Multicomponent [C+NC+CC] Coupling Reaction” Tetrahedron Lett, 2007,48 3867.

Book Chapters

McEnaney, P.J.*; Parker, C.G.*; Zhang, A.X.* “Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics,” Annu Rep Med Chem, 2018, 50, 481. (*co- corresponding authors)

Patents

1. Teijaro, J.; Parker, C.G. “Small Molecule Inhibitors of SLC15A4 with Anti-Inflammatory Activity” US Provisional Patent Application (Application No 62/981,907; Filed 03/2020).

2. Parker, C.G.; Correia, B.; Cravatt, B.F. “Photoreactive Ligands and Uses Thereof” US Patent Application (Application No. 62/447,882; Filed 07/16/2019)

3. Parker. C.G.; Spiegel, D.A. “Cytotoxic-Drug Delivering Molecules Targeting HIV (CDM- h’s), Cytotoxic Activity Against the Human Immunodeficiency Virus and Methods of Use” Patent No US20150087609 (Filed 03/15/2013; Published 03/15/2015)

3 Curriculum Vitae Christopher G. Parker, Ph.D 4. Parker. C.G.; Spiegel, D.A. “Preparation of Indolylpiperazinylethanedione Derivatives for Use as Bifunctional Compounds with Antibody-Recruiting and Viral Entry Inhibiting Activity Useful in Mono- and Combination Therapy of HIV Infections” Patent No WO2012068366 (Filed 11/17/2011; Published 5/24/2012)

5. Parker, C.G.; Spiegel, D.A. “Bifunctional Molecules with Antibody-Recruiting and Entry Inhibitory Activity Against the Human Immunodeficiency Virus,” Patent No. WO 2011046946. (Filed 10/12/2010, Published 4/21/2011); US9562038. (Filed 11/18/2011, Published 02/07/2017

Invited Seminars

1. Matteson Symposium, School of Pharmacy, Washington State University, Pullman WA, October 3, 2020 (expected). 2. Special Seminar, AbbVie Inc, IL, August 27, 2020 (expected). 3. The ABCs of SLCs: Why Transporters Make Great Targets, MEDI Division, American Chemical Society National Meeting, San Francisco, CA, August 19, 2020 (expected). 4. Florida Annual Meeting and Exposition (FAME), American Chemical Society Florida Section, Tarpon Springs FL, May 5, 2020 (Cancelled due to COVID19). 5. World Molecular Engineering Network (WMEN) Annual Conference, Los Cabos, Mexico, May, 2020 (Cancelled due to COVID19). 6. Seminar series, Department of Chemistry, Duquesne University, Pittsburgh, PA, April 23, 2020 (Cancelled due to COVID19). 7. Seminar series, Department of Chemistry, Case Western Reserve University, Cleveland, OH, February 26, 2020. 8. Special Seminar, Astex Pharmaceuticals, Cambridge, United Kingdom, July 4, 2019 9. World Molecular Engineering Network (WMEN) Annual Conference, Los Cabos, Mexico, May 5, 2019. 10. Seminar series, Department of Chemistry, Florida Atlantic University, Boca Raton, FL, November 9, 2018. 11. Emerging Trends in Target Identification, MEDI Division, American Chemical Society National Meeting, Boston, MA, August 19, 2018. 12. Spotlight Session, Chemical Biology, Drug Discovery and Bioanalytical Methods, American Society for Biochemistry and Molecular Biology (ASBMB), San Diego, CA, April 22, 2018 13. Special seminar, Center for Molecular Medicine (CeMM), Vienna, Austria, November 2017 14. SLC Transporters and Ion Channels in Drug Discovery and Preclinical Development, Biomedical Transporters 2017, Lausanne, Switzerland, August 7, 2017. 15. Bioorganic Chemistry Gordon Research Conference, Andover, NH, June 2017.

4 Curriculum Vitae Christopher G. Parker, Ph.D 16. Fragment-Based Drug Discovery, Cambridge Health Institute, San Diego, CA, April 25, 2017. 17. Omics Strategies to Study the Proteome, Functional Proteomics, Keystone Symposia, Breckinridge, CO, February 2, 2017. 18. The Scripps Research Institute Pathogenesis Affinity Group Retreat, San Diego, CA, January 2017. 19. Special seminar, Department of Chemistry, National Taiwan University, Taipei, Taiwan, November 18, 2016. 20. Special seminar, University of the Philippines – Manila, Manila, Philippines, April 2014.

Teaching Experience

Spring 2020 Drug Discovery and Development “Target ID, Validation and Drug Discovery,” Scripps Research. Fall 2019 Chemical Biology “Chemical Proteomics,” Scripps Research. Fall 2018 Chemical Biology “Chemical Proteomics,” Scripps Research. Fall 2020 Chemical Biology “Chemical Proteomics,” Scripps Research.

Committees

Graduate Admissions Committee, Scripps FL, (2019-present); Frontiers in Chemical Biology co-organizer, Scripps FL, (2019-present); Graduate Thesis Committees (currently 6 graduate students).

Professional Activities

American Cancer Society (2013-present) American Chemical Society (2009-present) Reviewer: Bioorganic and Medicinal Chemistry, Cell Chemical Biology, ChemBioChem, ChemMedChem, Chemical Science, Journal of the American Chemistry Society, Journal of Medicinal Chemistry, Molecular Systems Biology, Nature Chemical Biology, Organic & Biomolecular Chemistry, Scientific Reports

5 Curriculum Vitae Christopher G. Parker, Ph.D